Hill Top Home Of Comfort Inc | |
95 Hill Top Dr, Killdeer, North Dakota 58640 | |
(701) 764-5682 | |
Name | Hill Top Home Of Comfort Inc |
---|---|
Location | 95 Hill Top Dr, Killdeer, North Dakota |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 58 |
Occupancy Rate | 91.38% |
Medicare ID (CCN) | 355092 |
Legal Business Name | Hill Top Home Of Comfort Inc. |
Ownership Type | Non Profit - Corporation |
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
A combination of inexpensive oral medications may be able to treat fatigue-inducing anemias caused by chronic diseases and inflammation, a new discovery from the University of Virginia School of Medicine suggests.
A new medical device, the geko™, designed to increase blood circulation through neuromuscular electro–stimulation to the common peroneal nerve, has received the positive endorsement of Westmead Hospital, New South Wales, as an important new development in the prevention of Deep Vein Thrombosis (DVT).
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, announced that it has entered into a definitive securities purchase agreement with a group of select institutional investors to purchase US$10 million of its securities in a registered direct offering. No placement agent was utilized in connection with the offering.
Together with colleagues from Shanghai, Brussels, Canada and the USA, researchers from the University of Bonn have uncovered the binding mechanism of an important pain receptor.
PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.
› Verified 3 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 20.95 | 14.46 |
Percentage of long-stay residents who lose too much weight | 5.56 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 53.45 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.4 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 4.55 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 6.44 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 5.21 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 15.88 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 20.91 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.17 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 1.32 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 87.57 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 100 | 82.93 |
News Archive
A combination of inexpensive oral medications may be able to treat fatigue-inducing anemias caused by chronic diseases and inflammation, a new discovery from the University of Virginia School of Medicine suggests.
A new medical device, the geko™, designed to increase blood circulation through neuromuscular electro–stimulation to the common peroneal nerve, has received the positive endorsement of Westmead Hospital, New South Wales, as an important new development in the prevention of Deep Vein Thrombosis (DVT).
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, announced that it has entered into a definitive securities purchase agreement with a group of select institutional investors to purchase US$10 million of its securities in a registered direct offering. No placement agent was utilized in connection with the offering.
Together with colleagues from Shanghai, Brussels, Canada and the USA, researchers from the University of Bonn have uncovered the binding mechanism of an important pain receptor.
PROLOR Biotech, Inc., today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.
› Verified 3 days ago
Hill Top Home Of Comfort Inc Location: 95 Hill Top Dr, Killdeer, North Dakota 58640 Phone: (701) 764-5682 |